TNGXTango Therapeutics, Inc.
$23.82+213% 1Y
$23.82
$6.9152 weeks$32.90
The financials
Tango Therapeutics, Inc. by the numbers
Tango Therapeutics, Inc. (TNGX) reported revenue of $3.7M in Q2 2026 (quarter ended Jun 30, 2026), up 17% from the same quarter a year earlier. That came with net loss of $55M. For the full year FY2025, revenue was $62M (+48% year on year) and net income −$102M. Its largest product in Q2 2024 (quarter ended Jun 30, 2024) was License at $12M, 61% of the disclosed total, well ahead of Collaboration at 39%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $3.7M | $3.2M | +17% |
| Operating income | −$60M | −$41M | n/a |
| Net income | −$55M | −$39M | n/a |
| Diluted EPS | −$0.37 | −$0.35 | n/a |
| Product | Revenue | Share |
|---|---|---|
| License | $12M | 61% |
| Collaboration | $7.8M | 39% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q3 2025Total $53.8M (+1592%)
Collaboration grew +364% year on year
Segment Latestquarter on quarteryear on year
- Collaboration$53.8M$53.8Mquarter on quarter +1592%year on year +364%+1592%+364%
On our screens:Most shorted stocks